Agen expects return to revenue growth in 1996 - 1997
This article was originally published in Clinica
Executive Summary
Agen, the Australian diagnostics manufacturer, faces a double- edged problem, chairman R F Cormie told a recent annual general meeting. The company's R&D efforts over recent years have not resulted in the commercialisation of significant new diagnostic products and at the same time "revenues from existing products have flattened". Fiscal 1995 sales declined 12% to Aus$8.4 million ($6.4 million - see Clinica No 672, p 13).